UPDATE: Jefferies Starts Pluristem Therapeutics (PSTI) at Hold

Article Stock Quotes (1) Comments (0)

(Updated - March 19, 2013 7:10 AM EDT)

Jefferies initiates coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Hold. PT $3.50.

The firm comments, "Positives for PSTI include (1) real unmet need/large market potential in peripheral arterial disease (PAD) and (2) proprietary stem-cell technology platform & its potential for broad applicability. Challenges are (1) yet-to-be proven clinical efficacy of PLX cells; (2) Ph2 PLX-PAD data not until ~late-2014/early-2015; (3) difficult-to-treat PAD lead indication; and (4) potential clinical/regulatory hurdles for stem-cell products."

For an analyst ratings summary and ratings history on Pluristem Therapeutics click here. For more ratings news on Pluristem Therapeutics click here.

Shares of Pluristem Therapeutics closed at $3.08 yesterday, with a 52 week range of $2.10-$5.00.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
• Avondale Partners Starts Tractor Supply Company (TSCO) at Market Outperform
• WallachBeth Capital Starts NuVasive (NUVA) at Buy

Create E-mail Alert Related Categories

New Coverage

Related Entities

Jefferies & Co

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?